Posts by Dante Salvetti

AMA CPT Editorial Panel Acceptance of Five Category III Codes Establishes Coding Infrastructure for Bilateral Supraorbital-Occipital Neurostimulator Services Ahead of Anticipated Regulatory Submission

MINNEAPOLIS, June 2, 2026 /PRNewswire/ — ShiraTronics, Inc., a clinical-stage medical device company developing neuromodulation therapies for chronic migraine, today announced two milestones: the completion of enrollment in its RELIEV-CM2 pivotal trial, and the acceptance by the American Medical Association (AMA) CPT Editorial Panel of a dedicated five-code Category III set for bilateral supraorbital-occipital neurostimulator services. Arriving within the same window, the two developments point in the same direction. Patients and physicians completed pivotal enrollment at pace, signaling real demand for a new approach; the AMA, working independently, codified the procedure as distinct clinical work. Together they mark growing recognition of an emerging category, Implantable Extracranial Neuromodulation Systems (IENs) — of which the investigational ShiraTronics system is the first device purpose-built for chronic migraine.